Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoldonrasib + Chemotherapy in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
NCT07621718Phase 3Recruiting
- Sponsor
- Revolution Medicines
- Start
- May 2026
- Primary completion
- Dec 2028
- Countries
- 2
01
Overview
A Phase 3 trial of zoldonrasib in pancreatic adenocarcinoma (PDAC), sponsored by Revolution Medicines. Started May 2026; status: recruiting.
02
Drugs
zoldonrasib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07621718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07621718.